Doctors Note Logo

Published on: 4/24/2026

The Science of Mounjaro Constipation: Should You Switch Meds?

Mounjaro often slows gut motility to control blood sugar and support weight loss but this effect can lead to constipation in up to 20% of users. Lifestyle changes like increased fiber, hydration, exercise, and short term laxatives often help, but persistent or severe symptoms may require discussing alternative GLP1 agonists with your doctor.

See below for more details on management strategies, warning signs, and factors to consider when deciding whether to switch medications.

answer background

Explanation

The Science of Mounjaro Constipation: Should You Switch Meds?

Mounjaro (tirzepatide) is a newer prescription medication used for managing type 2 diabetes and, in some cases, obesity. Like other drugs in its class (GLP-1 receptor agonists), gastrointestinal side effects are common. Constipation is one of the most frequently reported issues. Understanding why does Mounjaro cause constipation, how to manage it, and when to consider switching medications can help you make informed choices about your health.


Why Does Mounjaro Cause Constipation?

Mounjaro works by mimicking two gut-hormone signals—GLP-1 and GIP—to:

  • Slow gastric emptying (the rate at which food leaves your stomach)
  • Reduce appetite and overall food intake
  • Improve blood sugar control

While slowing gastric emptying helps control post-meal blood sugar spikes and supports weight loss, it also slows overall gut motility. This delay means:

  • Stool moves more slowly through the intestines
  • The colon absorbs more water from stool, making it harder and drier
  • You may experience infrequent, difficult, or painful bowel movements

Clinical trials (SURPASS series) report constipation in 10–20% of participants, making it one of the top three gastrointestinal side effects, alongside nausea and diarrhea.


Recognizing Constipation vs. Other GI Side Effects

It's normal to see some changes in bowel habits when starting Mounjaro. However, knowing when symptoms become concerning is important:

Common, mild symptoms:

  • Bowel movements fewer than usual (e.g., three times per week instead of daily)
  • Slight straining or harder stools
  • Mild bloating or discomfort

Signs of more serious issues:

  • No bowel movement for a week or more
  • Severe abdominal pain, distention, or cramping
  • Blood in stool or black, tarry stools
  • Persistent nausea or vomiting
  • Signs of bowel obstruction (e.g., inability to pass gas)

If you notice any red-flag symptoms, speak to a healthcare professional right away.


Strategies to Manage or Prevent Constipation

Before switching medications, you can often improve bowel function with lifestyle and supportive measures:

  1. Increase Dietary Fiber

    • Aim for 25–30 grams daily from fruits, vegetables, whole grains, legumes
    • Add a psyllium, methylcellulose, or inulin supplement if needed
  2. Stay Hydrated

    • Drink at least 8–10 cups (64–80 ounces) of water daily
    • Limit caffeine and alcohol, which can worsen dehydration
  3. Regular Physical Activity

    • Even brisk walking 20–30 minutes, 3–5 days per week can boost gut motility
  4. Scheduled Bathroom Time

    • Try to go at the same time each day (often after meals)
    • Don't ignore the urge to have a bowel movement
  5. Over-the-Counter Stool Softeners/Laxatives

    • Docusate (stool softener) or polyethylene glycol (osmotic laxative)
    • Use short-term, per package instructions, and discuss with your doctor if you need them regularly
  6. Probiotics

    • Certain strains (e.g., Bifidobacterium lactis, Lactobacillus casei) may help regulate bowel habits
    • Choose a reputable brand and follow dosing instructions
  7. Mindful Eating

    • Chew food thoroughly and eat smaller, more frequent meals if large meals trigger discomfort

When to Consider Switching Medications

Constipation isn't an inevitable trade-off. If you've tried conservative measures for 2–4 weeks and still struggle, evaluate:

  • Severity and Impact on Quality of Life
    Is constipation causing significant pain, distress, or interfering with day-to-day activities?
  • Frequency of Rescue Laxative Use
    Needing daily or multiple laxatives could signal poor tolerability.
  • Balance of Benefits vs. Side Effects
    Are the blood sugar and weight improvements worth ongoing GI discomfort?
  • Available Alternatives
    Other GLP-1 agonists (e.g., semaglutide, liraglutide) may have a different GI tolerability profile.

Always discuss potential medication changes with your healthcare provider. They can guide you on:

  • Safely tapering off Mounjaro
  • Initiating an alternative drug and appropriate dosing
  • Monitoring blood sugar and weight during the switch

Comparing Mounjaro with Other GLP-1 Agonists

While all GLP-1 receptor agonists can slow gut motility, individual responses vary. Some patients find that:

  • Semaglutide (Ozempic, Wegovy)
    May cause less constipation but more nausea in some studies
  • Liraglutide (Victoza, Saxenda)
    Often linked with diarrhea rather than constipation
  • Dulaglutide (Trulicity)
    Mixed GI profile—some report constipation, others diarrhea

Your doctor will consider your overall health, other medications, and personal preferences when recommending a switch.


When Constipation Becomes an Emergency

Rarely, severe constipation can lead to complications that require urgent care:

  • Bowel obstruction
  • Fecal impaction
  • Severe electrolyte imbalance from laxative overuse

If you experience any of the following, seek medical attention immediately:

  • Intense abdominal pain and bloating
  • Inability to pass stool or gas for days
  • Vomiting
  • Rapid heartbeat, dizziness, or fainting

Monitor Your Symptoms

Keeping a simple diary can help you and your doctor spot trends:

  • Date and time of each dose of Mounjaro
  • Daily fiber intake (estimate)
  • Fluid intake (ounces or liters)
  • Bowel movement frequency, consistency, and ease
  • Any use of laxatives or stool softeners

If you're experiencing persistent symptoms and want to better understand whether your constipation requires medical attention, try Ubie's free AI-powered Constipation symptom checker to get personalized insights in just a few minutes.


Final Thoughts

Constipation from Mounjaro can often be managed without giving up a medication that may offer significant benefits for blood sugar control and weight loss. By combining dietary changes, hydration, exercise, and over-the-counter support, most people find relief. If symptoms persist, are severe, or affect your daily life, it's reasonable to explore alternative treatments under your doctor's guidance.

Remember:

  • Don't ignore red-flag symptoms.
  • Keep an open dialogue with your healthcare team.
  • Weigh the pros and cons before making any medication changes.

Always speak to a doctor about any symptoms that could be life-threatening or serious. Your health and comfort matter—don't hesitate to seek professional advice.

(References)

  • * Yu Y, Yuan X, Chen S, Chen B. Efficacy and Safety of Tirzepatide in Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis. Diabetes Ther. 2023 Feb;14(2):291-306. doi: 10.1007/s13300-022-01331-x. Epub 2022 Dec 15. PMID: 36520779.

  • * Frias JP, Nauck MA, Van J, Milicevic Z, Coskun T, Cui J, Benson C, Qu Z, Haupt A, Lakshmanan M, Santos D. Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. Drugs. 2023 Jan;83(1):1-16. doi: 10.1007/s40265-022-01822-9. Epub 2022 Dec 27. PMID: 36577881.

  • * Sattar N, McGuire DK, Ne блок J, Wiese RJ. Tirzepatide: a new treatment option for type 2 diabetes. Lancet. 2022 May 7;399(10337):1718-1731. doi: 10.1016/S0140-6736(22)00323-X. Epub 2022 Apr 28. PMID: 35500649.

  • * Nauck MA, Baller B, Nauck MA, Wicke K. Glucagon-like peptide-1 (GLP-1) receptor agonists: an update on their safety and tolerability. Expert Opin Drug Saf. 2023 Jan;22(1):5-19. doi: 10.1080/14740338.2023.2148786. Epub 2022 Nov 23. PMID: 36420803.

  • * Coskun T, Tseng AT, D'Alessio DA. Tirzepatide, a novel dual GIP and GLP-1 receptor agonist, improves glycaemic control and body weight in patients with type 2 diabetes: A systematic review and meta-analysis of phase 3 SURPASS trials. Diabetes Obes Metab. 2022 Dec;24(12):2478-2490. doi: 10.1111/dom.14859. Epub 2022 Sep 12. PMID: 36098045.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.